NCT06965998 - A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2027

Conditions

SVTThrombosisSuperficial Vein Thrombosis

Interventions

DRUG

Full dose rivaroxaban

The intervention group will receive full dose rivaroxaban for 90 days.

DRUG

Low dose rivaroxaban

The comparator group will receive the standard treatment of low dose rivaroxaban.

DRUG

Placebo

Since the treatment arm has an AM and PM dose of study drug from Day 1-21, the comparator group will take 1 placebo pill in the PM to keep the two arms blinded.

Trial Locations (2)

K1H 8L6

RECRUITING

The Ottawa Hospital, Ottawa

K1K 0T2

NOT_YET_RECRUITING

Hopital Montfort, Ottawa